[英文调查报告书] 新非专利药品市场：欧洲

Abstract

The four EU countries analysed in this report - France, Italy, Portugal, Spain - are expected to deliver significant double digit growth over the next 5 years and present stable, regulated operating environments with excellent prospects.

The many generic companies and investors looking to Asian and Latin American markets for generic drug market growth could be missing a trick! The four EU countries analysed in this report are expected to deliver significant double digit growth over the next 5 years and present stable, regulated operating environments with excellent prospects.

Key Areas Addressed:

5-year market forecasts to 2012 for the pharmaceutical and generic drug markets
Analysis of market trends and outlook of key developments
Domestic production and review of leading companies
Regulatory environment
Health provision and plans

THIS REPORT ANSWERS KEY QUESTIONS

Which therapy sector accounted for the greatest part of the Spanish generics market in 2006?
What measures are in place to reduce generic prices in Portugal?
How might developments in the French reference pricing system affect the generics market?
What developments with supplementary protection certificates will positively affect the Italian generics market after 2010?
What are the 8 leading active ingredients to lose patent protection in Italy in 2007?
How has generic pravastatin fared in the French statin market against simvastatin?

Foreword
Executive Summary
France
Introduction
- Key Data Projections, 2007-2012
Healthcare System
- Organisation
- Health Insurance System
- Health Expenditure
  - Health Expenditure, 1995-2006 (Billion Euros)
  - Medical Consumption by Service, 2000-2006 (Billion Euros)
  - Spending Trends on Pharmaceuticals & Medical Products in the Ambulatory Sector, 1995-2005 (%)
  - Medical Consumption by Source of Funding, 1995-2006 (%)
  - Medical Consumption by Sector & Source of Funding, 2005 (%)
Healthcare Infrastructure
- Hospital Resources
  - Hospital Services, 1995-2005
  - Public Hospitals by Type, 2004
  - Private Hospitals by Type, 2005
  - Private Hospitals by Status, 2004
  - Hospital Beds & Day Places by Specialty & Sector, 2005
- Hospital Activity
  - Hospital Activity, 2001-2005
  - Hospital Activity by Specialty, 2005
  - Patient Distribution by Most Frequent Diagnostic Groups in Public & Private Hospitals, 2004
  - Inpatient Activity in Public Short-Stay Units by Major Diagnostic Groups, 2003
  - Inpatient Activity in Private Short-Stay Units by Major Diagnostic Groups, 2003
- Ambulatory Resources
  - Independent Practitioners by Type of Practice, 2002 (%)
- Medical Personnel
  - Medical Personnel, 1995-2004
  - Doctors by Specialty & Sector, 2001-2003
Pharmaceutical Market Overview
- Size
  - Summary of the French Pharmaceutical Market, 2007
- Projections
  - Market Projections, 2007-2012
- Local Manufacturers
  - Mergers & Acquisitions of French Pharmaceutical Companies, 1995-2007
  - Pharmaceutical Companies Operating in France
Generic Market
- Size
  - Reimbursable Market by Patent Status, 2002-2006 (Million Euros)
  - Reimbursable Market by Patent Status, 2002-2006 (%)
  - Change in Reimbursable Market by Patent Status, 2002-2006 (%)
  - Reimbursable Market by Patent Status, 2002-2006 (Million Units)
  - Reimbursable Market by Patent Status, 2002-2006 (%)
  - Change in Reimbursable Market by Patent Status, 2003-2006 (%)
  - Reimbursable Market by Substitution, 2006
  - Substitutable Market by Reimbursement Status, 2005-2006 (Million Euros)
  - Subtitutable Market by Reimbursement Status, 2005-2006 (%)
- Projections
  - Projected Generics Market, 2007-2012 (US$ Billion)
- Outlook
  - Outcomes of the New Reference Pricing System
  - Increasing Prescribing of Generics
  - Generic Drugs to Reduce Health Expenditure by 912 Million Euros in 2006
    - Trends in Generic Drug Consumption, 2003-2006
  - France Transposes EU Pharmaceutical Directive
  - Pharmacists Associations Agree New Generics Target for 2007
    - Generics Penetration Objectives by Volume, 2006
    - Generics Penetration Objectives by Volume, 2007
- SWOT
  - SWOT Analysis of the French Generics Market, 2007
- Trade Association
  - Members of GEMME, 2007
- Domestic Production
  - Leading French Generic Producers, 2005-2006 (%)
- Local Manufacturers
  - Arrow Génériques
  - Biogaran
  - Bouchara-Recordati
  - EG-Labo
    - EG-Labo' s Sales, 2002-2006 (Million Euros)
    - EG-Labo' s Sales as % of Stada' s Sales, 2002-2006
- Merck Génériques
  - Merck Génériques' Financial Indicators, 2003-2006
- Ranbaxy
  - Ranbaxy Pharmacie Génériques' Sales, 2004-2006 (US$ Million)
- ratiopharm
  - ratiopharm France' s Sales, 2004-2006 (Million Euros)
- Sandoz
  - Sandoz France' s Sales, 2001-2006 (Million Euros)
- Teva
- Winthrop
- Wockhardt
- Zydus France
  - Zydus France' s Sales, 2003-2005
Regulatory Environment
- Registration
- Pricing & reimbursement
  - Pricing
  - Pricing of Reimbursable Medicines in the Retail Pharmacy Market
  - Price Revisions
  - Pricing Activity
    - Drug Pricing Applications Submitted by Type, 2006
    - Average Number of Days Taken to Process First-Time Registrations, 2006
  - Pharmacy Margins
  - Reference Pricing (TFR)
  - Pricing of Hospital Medicines
  - Reimbursement
    - Distribution of the Pharmaceutical Market According to Reimbursement Rate, 2006
- Intellectual Property
  - Leading Active Ingredients Coming off Patent, 2005-2007
- Supplementary Protection Certificates
Generics in the French PPI Market
- PPIs on the French market, 2007
- Reimbursable Sales of PPPIs (Régime Générale), 2002-2006 (Million Euros)
- Reimbursable Sales of PPPIs (Régime Générale), 2002-2006 (%)
- Reimbursable Sales of PPPIs (Régime Générale), 2002-2006 (Million Units)
- Reimbursable Sales of PPPIs (Régime Générale), 2002-2006 (%)
- Reimbursable Sales of PPPIs (Régime Générale), 2002-2006 (Average Unit Price, Euros)
- Reimbursable Sales of PPIs by Patent Status (Régime Générale), 2004-2006 (Million Euros)
- Reimbursable Sales of PPIs by Patent Status (Régime Générale), 2004-2006 (Million Units)
Omeprazole and esomeprazole
- Omeprazole Sales Data (Régime Générale), 2004-2006 (Million Euros)
- Omeprazole Sales Data (Régime Générale), 2004-2006 (Million Units)
- Esomeprazole & Omeprazole Sales Data (Régime Générale), 2002-2006 (Million Euros)
- Esomepraole & Omeprazole Sales Data (Régime Générale), 2002-2006 (Million Units)
Generics in the French Statins Market
- Statins on the French Market, 2007
- Reimbursable Sales of Statins (Régime Générale), 2002-2006 (Million Euros)
- Reimbursable Sales of Statins (Régime Générale), 2002-2006 (%)
- Reimbursable Sales of Statins (Régime Générale), 2002-2006 (Million Units)
- Reimbursable Sales of Statins (Régime Générale), 2002-2006 (%)
- Average Unit Price of Statins (Régime Générale), 2002-2006 (Euros)
- Reimbursable Sales of Statins & Ezetimibe (Régime Générale), 2002-2006 (Million Euros)
- Reimbursable Sales of Statins by Patent Status (Régime Générale), 2005-2006 (Million Euros)
- Reimbursable Sales of Statins by Patent Status (Régime Générale), 2005-2006 (Million Units)
Pravastatin
- Pravastatin Sales Data (Régime Générale), 2006
Simvastatin
- Simvastatin Sales Data (Régime Générale), 2005-2006 (000s Euros)
- Simvastatin Sales Data (Régime Générale), 2005-2006 (000s Units)
- Simvastatin + Ezetimibe Sales Data (Régime Générale), 2005-2006 (Million Euros)
- Simvastatin + Ezetimibe Sales Data (Régime Générale), 2005-2006 (Million Units)
Directory
- Government Organisations
- Generic Trade Association
- Generic Manufacturers
Italy
Introduction
- Key Data Projections, 2007-2012
Healthcare System
- Organisation
- Health Expenditure
- Health Expenditure, 2000-2006 (Million Euros)
- Public Health Expenditure by Type, 2000-2006 (Million Euros)
- Public Health Expenditure by Region & Type, 2006 (Million Euros)
- Private Health Expenditure by Region, 1998-2003 (Million Euros)
Healthcare Infrastructure
- Hospital Resources
  - Inpatient Institutions by Type, 2000-2005
  - Inpatient Institutions by Region, 2000-2005
  - Hospital Beds by Type, 2005
  - Hospital Beds, 1997-2005
  - Hospital Beds by Region, 2005
- Hospital Activity
  - Hospital Activity, 2000-2004
  - Hospital Activity by Sector, 2004
  - Public Acute Hospital Activity by Region, 2004
  - Private Accredited Acute Hospital Activity by Region, 2004
  - Hospital Activity by Diagnosis Group, 2004
- Ambulatory Resources
  - Guardia Medica Points by Region, 2005
  - Ambulatory & Other Facilities, 2005
  - Ambulatory & Other Facilities by Type of Service, 2000-2005
- Ambulatory Activity
  - Clinical, Laboratory & Diagnostic Procedures, 2005
- Medical Personnel
  - Registered Doctors by Region, 2006
  - SSN Personnel, 2000-2005
Pharmaceutical Market Overview
- Size
  - Summary of the Italian Pharmaceutical Market, 2007
  - Number of Pharmaceutical Products & Presentations, 2000-2006
  - Number of SSN Pharmaceutical Products & Presentations, 2000-2007
- Projections
  - Market Projections, 2007-2012
- Local Manufacturers
Generic Market
- Size
  - Net SSN Sales by Patent Status, 2002-2006 (Million Euros)
  - Net SSN Sales by Patent Status, 2002-2006 (%)
  - Change in Net SSN Sales by Patent Status, 2003-2006 (%)
  - Generics Sales as % of Net SSN Sales by Region, 2002-2006
  - Per Capita Net SSN Generics Expenditure by Region, 2002-2006 (Euros)
  - Net SSN Generics Sales by Region, 2002-2006 (DDD/1,000 Population)
  - Generics Sales as % of Net SSN Sales by Region, 2002-2006 (DDD/1,000 Population)
  - Gross SSN Generics Sales by Leading Active Ingredient, 2006 (Million Euros)
  - Gross SSN Generics Sales by Leading Active Ingredient, 2006 (DDD)
- Projections
  - Projected Unbranded Generic Market, 2007-2012
- Outlook
  - SWOT Analysis of the Italian Generics Market, 2007
- Domestic Production
  - Leading Italian Generic Producers, 2007
- Trade Association
  - ASSOGENERICI
    - Members of ASSOGENERICI, 2007
- Local Manufacturers
  - Angenerico
    - Angelini' s Pharmaceutical Companies, 2006
  - DOC Generici
  - Eurogenerici
    - Eurogenerici' s Sales, 2002-2006 (Million Euros)
    - Eurogenerici' s Sales, 2002-2006 (%)
    - Eugenerici' s Sales as % of Stada' s Sales, 2002-2006 (%)
  - Hexan
  - Merck Generics Italia
    - Merck Generics Italia' s Sales, 2004-2006 (Million Euros)
  - Pliva Pharma
    - Pliva Italia' s Sales, 2003-2005 (US$ Million)
  - Ranbaxy
  - ratiopharm Italia
  - Sandoz
    - Sandoz' s Italian Sales within the Novartis Group, 2004-2005 (Million Euros)
  - Teva Pharma Italia
    - Teva Pharma Italia' s Production Capabilities, 2006
Regulatory Environment
- Pricing & Reimbursement
  - EU Directive on the Transparency of Pricing & Reimbursement
  - Reimbursement
- Intellectual Property
  - National Supplementary Protection Certificate
    - Leading Active Ingredients with Patents Close to Expiry, 2007
- Directory
  - Government Organisations
  - Generic Trade Associations
  - Generic Manufacturers
Portugal
Introduction
- Key Data Projections, 2007-2012
Healthcare System
- Organisation
  - Organic Health Law No. 10/1993
    - Health Regions, 1993
  - Decree Law No. 257/2001
- Health Expenditure
  - Projected Health Expenditure, 2006-2012
  - Health Expenditure, 2000-2005 (Million Euros)
- Healthcare Infrastructure
  - Hospital Resources
    - Public & Private Hospitals, 1990-2005
    - Public & Private Hospitals by Region, 2005
    - General & Specialty Hospitals by Type, 2005
    - Hospital Beds & Operating Rooms, 1990-2005
  - Hospital Activity
    - Hospital Admissions, 1990-2005
    - Hospital Admissions by Region, 2005
    - Hospital Admissions by Hospital Type, 2005
    - Admissions, Discharges & Patient Days by Hospital Specialty, 2005
    - Hospital Consultations by Specialty, 1990-2005 (000s)
    - Hospital Consultations by Specialty & Region, 2005 (000s)
    - Hospitals Diagnostic Procedures, 2001-2005
    - Public & Private Hospitals Therapeutic Procedures, 2005
  - Outpatient Resources
    - Outpatient Health Centres, Sub-Centres & Beds, 1990-2005
  - Outpatient Activity
    - Outpatient Admissions & Days, 1990-2005
    - Outpatient Admissions & Days by Region, 2005
    - Outpatient Consultations by Specialty, 1990-2005 (000s)
  - Medical Personnel
Pharmaceutical Market Overview
- Size
  - Summary of the Portuguese Pharmaceutical Market at Retail Prices, 2007
- Projections
  - Market Projections, 2007-2012
- Local manufacturers
  - INFARMED' s Listed National Manufacturers, 2007
Generic Market
- Size
  - Generics Pharmacy Sales by Value & Volume, 2003-2006
  - Generics Pharmacy Sales by Month, 2003-2006 (Million Euros)
  - Generics Pharmacy Sales by Month, 2003-2006 (000 Units)
  - Generics as a Percentage of the Pharmacy Sector by Volume, 2003-2006
  - Generics Pharmacy Sales by Therapeutic Area, 2006 (Million Euros)
  - Generics Pharmacy Sales by Therapeutic Area, 2006 (Million Units)
  - Generics Pharmacy Sales by Leading Active Ingredient, 2006 (Million Euros)
  - Generics Pharmacy Sales by Leading Active Ingredient, 2006 (Million Units)
- Projections
  - Projected Generics Market, 2007-2012
- Outlook
- SWOT
  - SWOT Analysis of the Portuguese Generics Market, 2007
- Trade Association
  - APOGEN
    - Members of APOGEN, 2007
- Domestic Production
  - Leading Portuguese Generic Producers, 2007
  - Leading Generic Producers in the Pharmacy Sector, 2005 (%)
- Local Manufacturers
  - Actavis
  - Alter
  - Bluepharma
  - Ciclum Farma
    - Ciclum Farma' s Sales, 2005-2006 (Million Euros)
  - Generis
  - Germed
  - Hovione
  - Labesfal
  - Medinfar
  - Merck Genéricos
  - Ranbaxy
  - ratiopharm
  - Sandoz
- Tecnimede
  - Tecnimede' s Financial Indicators, 2003-2007
  - Tecnimede' s Employees by Company, 2007
- ToLife
- Winthrop
Regulatory Environment
- Registration
  - Market Authorisations of Generic Medicines in the Pharmacy Sector, 2004-2007
  - Change in Market Authorisations of Generic Medicines in the Pharmacy Sector, 2005-2007 (%)
  - Market Authorisations of Generic Presentations, 2004-2007
  - Change in Market Authorisations of Generic Presentations, 2005-2007 (%)
- Pricing & Reimbursement
  - Generics Presentations by Reimbursement Status & Price Range, 2005
- Reimbursement
- EU Directive on the Transparency of Pricing & Reimbursement
  - Reimbursements
    - Generic Medicines by Reimbursement & Prescription Status, 2005
    - Generic Presentations by Reimbursement & Prescription Status, 2005
    - Generic Medicines & Presentations by Reimbursement Level, 2005
    - Generic Presentations by Reimbursement Level & Therapeutic Group, 2005
- Intellectual Property
  - European Supplementary Protection Certificate
  - Organon Commences Tibolone Patent Infringement Litigation in Portugal
Directory
- Government Organisations
- Generic Trade Association
- Generic Manufacturers
Spain
Introduction
- Key Data, 2007-2012
Healthcare System
- Organisation
  - Health Cohesion & Quality Law
- Health Expenditure
  - Projected Health Expenditure, 2007-2012
- Healthcare Infrastructure
  - Hospital Resources
    - Hospitals by Provision & Region, 2006
    - Hospitals by Provision & Specialty, 2006
    - Hospitals, 1985-2006
    - Hospital Beds by Provision & Region, 2006
    - Hospital Beds by Provision & Specialty, 2006
    - Hospital Beds, 1985-2006
  - Hospital Activity
    - Hospital Activity by Provision, 2005
    - Hospital Activity by Specialty, 2005
    - Hospital Discharges by Hospital Type & Specialty, 2005
    - Hospital Discharges, 1994-2005
  - Ambulatory Resources
    - Primary Care Consultations, 1994 & 2003
  - Medical Personnel
    - Registered Medical Personnel, 2000-2006
    - Practising Medical Personnel, 2006
Pharmaceutical Market Overview
- Size
  - Summary of the Spanish Pharmaceutical Market, 2007
- Projections
  - Market Projections, 2007-2012
- Local Manufacturers
  - Leading Pharmaceutical Companies in Spain, 2006
Generic Market
- Size
  - Generics Pharmacy Sales by Value & Volume, 2002-2006
  - Pharmacy Sales Value & Volume by Patent Status, 2006
  - SNS Pharmaceutical Sales by Patent Status, 2000-2005 (Million Euros)
  - SNS Pharmaceutical Sales by Patent Status, 2000-2005 (%)
  - Change in SNS Pharmaceutical Sales by Patent Status, 2000-2005 (%)
  - SNS Pharmaceutical Sales by Patent Status, 2000-2005 (Million Units)
  - SNS Pharmaceutical Sales by Patent Status, 2000-2005 (%)
  - Change in SNS Pharmaceutical Sales by Patent Status, 2000-2005 (%)
  - SNS Prescription Cost by Patent Status, 2000-2005 (Euros)
- Projections
  - Projected Generics Market, 2007-2012
- Outlook
  - Biosimilars' Substitution, Not a Viable Option in Spain
  - Regional INN Prescribing
    - Regional Generic Penetration
  - The II Iberian Simposium on Generics
    - Findings of the Study on Generics Perception, October 2005
- SWOT
  - SWOT Analysis of the Spanish Generics Market, 2007
- Trade Association
  - AESEG
    - Members of AESEG, 2007
- Local Manufacturers
  - Leading Spanish Generic Producers, 2007
  - Companies with Generics in the Market, January 2007
  - Number of Companies with Generics in the SNS Market, 2000-2006
  - Companies by Number of Generics in the SNS Market, 2000-2006
  - Companies by Number of Generics in the SNS Market, 2006
- Adamed
- Alter
  - Alter' s Financial Indicators, 2005-2006
- Barr
- Cantabria Pharma
- Cinfa
- Combino Pharm
- DOMAC
- Dr Reddy' s
- Kern Pharma
- Mabo-Farma
- Merck
- Normon
  - Normon' s Financial Indicators, 1997-2006
- Pharmagenus
- Ranbaxy
  - Ranbaxy Spain' s Sales, 2004-2006 (US$ Million)
- ratiopharm
- Sandoz
  - Novartis España' s Sales by Division, 2000-2005 (Million Euros)
  - Novartis España' s Employees by Division, 2000-2005
  - Sandoz' s Leading Generics, 2005
- Stada
  - Laboratorio Stada' s Sales, 2003-2006 (Million Euros)
- Teva
Regulatory Environment
- Registration
  - Active Ingredients & Presentations of Generic Medicines, 2000-2006
  - Presentations by Patent Status, 2006
  - Presentations of Generic Medicines by Administration Type, 2000-2006
  - Presentations of Generic Medicines by Administration Type, 2000-2006 (%)
  - Active Ingredients & Presentations of Generic Medicines by Therapeutic Area, 2006
  - Active Ingredients with the Highest Number of Generic Presentations, 2000-2006
  - Active Ingredients with the Highest Number of Presentations by Patent Status, 2006
- Pricing & Reimbursement
  - Co-Payments
    - Co-Payments, 2006
  - RPS Analysis
    - SNS Pharmaceutical Sales by the Reference Price System, 2005 (%)
  - Generic Pricing
    - Retail Prices of Presentations of Generic Medicines by Type, 2002-2006 (Euros)
  - Intellectual property
    - European Supplementary Protection Certificate
- Directory
  - Government Organisations
  - Generic Trade Association
  - Generic Manufacturers

欧洲新非专利药品市场

Emerging Generic Drug Markets in Europe

Abstract

Key Areas Addressed:

THIS REPORT ANSWERS KEY QUESTIONS

Table of Contents